Prophylix Pharma AS

Prophylix Pharma

This company develops antibody therapies to treat fetal and neonatal alloimmune thrombocytopenia in unborn babies and newborns.

HemaB

Hemab Therapeutics develops prophylactic antibody therapies for patients with rare bleeding and thrombotic disorders including Glanzmann thrombasthenia and Factor VII deficiency.

Hemab Therapeutics

This biotechnology company develops prophylactic antibody-based therapies for patients with rare bleeding and thrombotic disorders such as Glanzmann thrombasthenia and von Willebrand disease.

Tellus Therapeutics

This company develops biopharmaceutical treatments for white matter brain injury in premature infants to improve neurodevelopmental outcomes.

ProFactor Pharma

This company develops recombinant Factor VIII to treat haemophilia A in patients who currently lack access to affordable medication.

Clotprotect Therapeutics

This company develops small molecule anti-fibrinolytic drugs for patients suffering from acute haemorrhage and severe bleeding.

Acticor Biotech

The company develops glenzocimab, a therapeutic antibody fragment for treating patients with acute ischemic stroke and other thrombotic diseases.

TargED Biopharmaceuticals

The company develops targeted biological drugs to treat thrombotic diseases such as acute ischaemic stroke and immune-mediated thrombotic thrombocytopenic purpura for healthcare providers.